Global Favipiravir Market Growth 2025-2031

Global Favipiravir Market Growth 2025-2031

The global Favipiravir market size is predicted to grow from US$ 39.4 million in 2025 to US$ 8.3 million in 2031; it is expected to grow at a CAGR of -22.8% from 2025 to 2031.

Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.

In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.

LP Information, Inc. (LPI) ' newest research report, the “Favipiravir Industry Forecast” looks at past sales and reviews total world Favipiravir sales in 2024, providing a comprehensive analysis by region and market sector of projected Favipiravir sales for 2025 through 2031. With Favipiravir sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Favipiravir industry.

This Insight Report provides a comprehensive analysis of the global Favipiravir landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Favipiravir portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Favipiravir market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Favipiravir and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Favipiravir.

This report presents a comprehensive overview, market shares, and growth opportunities of Favipiravir market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Brand Drug
Generic Drug

Segmentation by Application:
Influenza Viruses
COVID-19
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Favipiravir market?

What factors are driving Favipiravir market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Favipiravir market opportunities vary by end market size?

How does Favipiravir break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.